Clinical Trials Browser

Recruiting × Interventional × selinexor × Clear all

NCT05099003 2026-04-14

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Phase 1/2 Recruiting

Glioma

NCT05333458 2026-04-13

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial

Phase 2 Recruiting

Sarcoma, Alveolar Soft Part

NCT07200102 2026-03-23

Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT06158841 2026-03-13

CERVINO

Phase 3 Recruiting

Multiple Myeloma

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT05530421 2026-02-23

SELVEDge

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT06517511 2026-02-12

Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04414475 2026-02-02

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Phase 2 Recruiting

Multiple Myeloma

NCT05611931 2026-02-02

XPORT-EC-042

Phase 3 Recruiting

Endometrial Neoplasms

NCT06239272 2026-01-26

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Phase 1/2 Recruiting

Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT05985161 2025-11-26

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Phase 2 Recruiting

GenitourinarySarcoma

Wilms Tumor, Neurofibrosarcoma, Rhabdoid Tumor

NCT04442022 2025-10-03

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2/3 Recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02227251 2025-10-01

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Recruiting

244 enrolled 3 FDA

Lymphoma, Large B-Cell, Diffuse

NCT07011056 2025-09-19

A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

Phase 3 Recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06822972 2025-09-02

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

Phase 2 Recruiting

Multiple Myeloma

NCT05900882 2025-08-17

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

Phase 2 Recruiting

Multiple Myeloma

NCT05035745 2025-07-25

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Phase 1/2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06114004 2025-06-25

SeliSarc

Phase 2 Recruiting

Sarcoma

NCT07002099 2025-06-03

Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study

Phase 2 Recruiting

Lymphoma

NCT06853678 2025-03-03

Second-line Immunotherapy for ES-SCLC

Phase NA Recruiting

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05597345 2025-02-10

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Phase 2 Recruiting

Smoldering Multiple Myeloma, Multiple Myeloma, Neoplasms, Plasma Cell

NCT06225310 2025-01-16

KPT-IST-391

Phase 1 Recruiting

Multiple Myeloma

NCT05726110 2024-10-22

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Phase 3 Recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05422027 2024-06-17

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT05983276 2024-02-08

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Phase 2 Recruiting

Ovarian Neoplasms, Recurrence

NCT04595994 2024-01-23

SeliSarc

Phase 1 Recruiting

Sarcoma

NCT05736965 2023-03-15

SAV

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute